Add Yahoo as a preferred source to see more of our stories on Google. Sep. 24—(StatePoint) Getting the correct treatment for bronchiectasis, a chronic lung condition affecting 350,000 to 500,000 ...
Bronchiectasis is a chronic respiratory disorder characterised by irreversible dilation of the bronchi, leading to impaired mucociliary clearance, recurrent infections and progressive respiratory ...
Bronchiectasis guidelines are inconsistent with regard to the effectiveness of mucoactive agents, and their use varies geographically. Large trials are needed to assess safety and effectiveness. For ...
If you have non-cystic fibrosis bronchiectasis, you’re likely an expert on the “lung side” of the disease — the stubborn mucus, the nagging cough, and the constant threat of a flare-up. But by causing ...
Brensocatib is the first approved therapy for non–cystic fibrosis bronchiectasis and the first dipeptidyl peptidase 1 inhibitor for neutrophil-mediated diseases. The ASPEN trial showed brensocatib ...
A simple at-home program with daily exercise, airway clearance, and nurse support helps patients breathe easier, offering new hope for millions living with this chronic lung disease. Study: Role of ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results